Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare ADALIMUMAB-RYVK (Simlandi) and INFLIXIMAB-DYYB (INFLECTRA) — clinical data, side effects, and patient experiences.
Simlandi · TNF Inhibitor
How it works
12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse...
Approved for
INFLECTRA, Remicade · TNF Inhibitor
How it works
12.1 Mechanism of Action Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit bin...
Approved for
Estimated frequency (%) based on clinical trial data
Based on 17 Reddit discussions
ADALIMUMAB-RYVK
29%
positive
7 threads
INFLIXIMAB-DYYB
10%
positive
10 threads
% of discussions mentioning each side effect
7 Reddit threads analysed for ADALIMUMAB-RYVK
Overall Sentiment
Mixed
Comparison Threads
0
Avg Post Score
4 upvotes
Most discussed side effects in community
I’m a 49M Crohn’s veteran, pretty new to Reddit. I’ve been on Humira for the past 10 years with fantastic results. By far the longest remission period since I was diagnosed in 1986. Last summer I had a skin cancer spot on my ear, a basal cell. Had it removed via Moh’s surgery. Now I have another spo
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Lt
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced t
* In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI * SELARSDI is the second biosimilar to launch in the U.S. under t
February 23, 2024 8:15 PM SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for intercha
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration interchangeable biosimilar to Hum
* Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis * The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection i
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
10 Reddit threads analysed for INFLIXIMAB-DYYB
Overall Sentiment
Mixed
Comparison Threads
0
Avg Post Score
47 upvotes
Most discussed side effects in community
I’m a hospital worker so I was able to get the vaccine (Pfizer brand) today. I wanted to share my experience with everyone as I had a lot of fear and doubts about getting it myself. Everything went extremely well, so far I have no side effects at all and it’s been about 4 hours. My arm doesn’t even
I’m bored and have a funny story, so I thought I’d share. I’m in the worst Crohn’s flare up thing of my life, which was brought on by a series of traumatic experiences. Inflectra/Remicade/Infliximab doesn’t work on me anymore apparently and neither do steroids, so my doctor changed me to Entivio re
Hi everyone, I had the idea of putting together a community developed survey for those of us diagnosed with Crohn's disease. The survey could allow us to gain insights into many different aspects of the Crohn's community. I am curious if anyone has some questions they would like to be included, if
Long of the short I was diagnosed with UC in 2020. Took mesalamine until December of 2025. Two flares one in October 2024 (lost 30 lbs) second and ongoing flare July 2025-present. I can’t gain any weight back. I started Inflectra in Feb of 2026 and just had my second dose. I am currently in a flare
I'm starting on Inflectra on Friday, and I'm a bit nervous, wondering: what might I expect? What I can bring to make the experience better? I have Crohn's and perianal disease (with two draining setons from a recent surgery). Planning on bringing some audiobooks, my donut pillow, and some snacks, bu
QUICK BIO: Was first diagnosed with UC in 2015. Was fairly moderate until 2020, when worsening symptoms led me to starting infusions of Inflectra. Was on that steady for nearly three years until my GI took me off of it because my inflammation markers still weren't looking good enough. I was on zero
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
Both ADALIMUMAB-RYVK and INFLIXIMAB-DYYB belong to the TNF Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. ADALIMUMAB-RYVK is administered via Subcutaneous, whereas INFLIXIMAB-DYYB uses Intravenous. Route of administration can affect onset of action and patient adherence.
Both medications are approved for inhibiting the progression of structural damage, inhibiting the progression of structural damage. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
ADALIMUMAB-RYVK carries 4 FDA warnings. INFLIXIMAB-DYYB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.